|
|
| (3 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| {{Chronic lymphocytic leukemia}}
| | [[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Chronic_lymphocytic_leukemia]] |
| {{CMG}} {{AE}}{{HL}} {{HK}} | | {{CMG}} {{AE}}{{HL}} {{HK}} |
| ==Overview== | | ==Overview== |
| * Chronic lymphocytic leukemia must be differentiated from other diseases that cause [[weight loss]], [[night sweats]], [[hepatosplenomegaly]], and palpable [[lymph node]]s, such as [[hairy cell leukaemia]], [[Prolymphocytic leukemia|prolymphocytic leukaemia]], [[follicular lymphoma]], and [[mantle cell lymphoma]].<ref name="H">Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref>
| | Chronic lymphocytic leukemia must be differentiated from other diseases that cause [[weight loss]], [[night sweats]], [[hepatosplenomegaly]], and palpable [[lymph node]]s, such as [[hairy cell leukaemia]], [[Prolymphocytic leukemia|prolymphocytic leukaemia]], [[follicular lymphoma]], and [[mantle cell lymphoma]]. |
|
| |
|
| ==Differenting Chronic lymphocytic leukemia from other Diseases== | | ==Differenting Chronic lymphocytic leukemia from other Diseases== |
| ===Differentials based on Biomarkers===
| | Chronic lymphocytic leukemia must be differentiated from other diseases that cause [[weight loss]], [[night sweats]], [[hepatosplenomegaly]], and palpable [[lymph node]]s, such as [[hairy cell leukaemia]], [[Prolymphocytic leukemia|prolymphocytic leukaemia]], [[follicular lymphoma]], and [[mantle cell lymphoma]]. |
| * Chronic lymphocytic leukemia must be differentiated from other diseases that cause [[weight loss]], [[night sweats]], [[hepatosplenomegaly]], and palpable [[lymph node]]s, such as [[hairy cell leukaemia]], prolymphocytic leukaemia, [[follicular lymphoma]], and [[mantle cell lymphoma]].
| |
| * Based on the expression of cell surface markers, the table below differentiates chronic lymphocytic leukemia from other diseases that cause similar clinical presentations:<ref name="H">Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref>
| |
| <br>
| |
| {| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
| |
| | valign="top" |
| |
| |+
| |
| ! style="background: #4479BA; width: 600px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}}
| |
| ! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Surface Immunoglobulin'''}}
| |
| ! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''CD5'''}}
| |
| ! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|'''CD22/FMC7'''}}
| |
| ! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''CD23'''}}
| |
| ! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''CD79b'''}}
| |
| ! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''CD103'''}}
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| |
| '''Chronic lymphocytic leukemia'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Weakly positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive/Negative'''
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| |
| '''[[Prolymphocytic leukemia]]'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | |
| '''Strongly positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| |
| '''[[Hairy cell leukemia]]'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Strongly positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive/Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive'''
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| |
| '''[[Mantle cell lymphoma]]'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Strongly positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Strongly positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
| |
| '''[[Follicular lymphoma]]'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Strongly positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Strongly positive'''
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| |
| '''Negative'''
| |
| |}
| |
| <br>
| |
| * Chronic lymphocytic leukemia must also be differentiated from other causes of fever, hepatosplenomegaly, and lymph node swelling such as:
| |
| :* [[Splenic marginal zone lymphoma]]
| |
| :* Nodal marginal zone [[lymphoma]]
| |
| :* [[Lymphoplasmacytic lymphoma]]
| |
| :* [[Sézary syndrome]]
| |
| :* Smoldering [[adult T cell leukemia]]
| |
| | |
| ===Other Differentials===
| |
| The following table differentiates chronic lymphocytic leukemia from other leukemias that may present with similar clinical features such as [[fever]], [[fatigue]], [[weight loss]], recurrent [[infections]] and elevated [[leukocyte counts]]. The following are the differentials:
| |
| | |
| {| class="wikitable"
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Characteristic
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Causes
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory abnormalities
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Physical examination
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Therapy
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other associations
| |
| |-
| |
| |[[Acute myeloid leukemia|'''Acute myeloid leukemia''']]
| |
| |
| |
| * [[Chromosomal]] instability
| |
| * Sporadic [[mutations]]
| |
| * Prior exposure to [[benzene]]
| |
| * Prior exposure to alkylating agents
| |
| * Prior exposure to [[Topoisomerase II|topoisomerase II inhibitors]]
| |
| * [[Germline]] ''[[RUNX1]]'' [[mutation]]
| |
| |
| |
| * [[Anemia]]
| |
| * [[Thrombocytopenia]]
| |
| * [[Neutropenia]]
| |
| * Elevated [[LDH]]
| |
| * Elevated [[uric acid]]
| |
| * Elevated [[phosphorus]]
| |
| * Elevated [[potassium]]
| |
| * Low [[calcium]]
| |
| * Greater than 20% [[myeloblasts]] on [[bone marrow]] aspirate<ref name="pmid27895058">{{cite journal| author=Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al.| title=Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. | journal=Blood | year= 2017 | volume= 129 | issue= 4 | pages= 424-447 | pmid=27895058 | doi=10.1182/blood-2016-08-733196 | pmc=5291965 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27895058 }} </ref>
| |
| |
| |
| * [[Pyrexia]]
| |
| * Evidence of [[infection]]
| |
| * [[Pallor]]
| |
| * [[Mucosal]] [[bleeding]] (less common than in [[acute promyelocytic leukemia]])
| |
| * [[Bruising]] (less common than in [[acute promyelocytic leukemia]])
| |
| |
| |
| * [[Cytarabine]]
| |
| * [[Anthracycline]]
| |
| * [[Enasidenib]]
| |
| * [[Liposomal]] [[daunorubicin]] plus [[cytarabine]]
| |
| * [[Gemtuzumab ozogamicin|Gemtuzumab ozogamycin]]
| |
| * [[Midostaurin]]
| |
| * [[Enasidenib]]
| |
| * Ivosidenib
| |
| * [[Stem cell transplant]]
| |
| |
| |
| * Variable [[prognosis]] based on [[cytogenetic]] and molecular profile
| |
| * Five new [[Food and Drug Administration|FDA]]-approved therapies became available in 2017-2018
| |
| |-
| |
| |[[Acute promyelocytic leukemia|'''Acute promyelocytic leukemia''']]
| |
| |
| |
| * Prior exposure to alkylating agents
| |
| * Prior exposure to [[topoisomerase II]] inhibitors
| |
| * [[Chromosomal translocation|Translocation]] between [[Chromosome 15 (human)|chromosomes 15]] and [[Chromosome 17 (human)|17]]
| |
| * Creation of PML-RAR''alpha'' [[gene]] product
| |
| * Differentiation block in [[myeloid cells]]
| |
| |
| |
| * Low [[white blood cell]] count (typically)
| |
| * [[Anemia]]
| |
| * [[Neutropenia]]
| |
| * [[Thrombocytopenia]]
| |
| * Low [[fibrinogen]]
| |
| * Elevated prothrombin time (PT)
| |
| * Elevated partial thromboplastin time (PTT)
| |
| |
| |
| * [[Mucosal bleeding]]
| |
| * [[Petechiae]]
| |
| * [[Ecchymoses]]
| |
| * Evidence of [[infection]]
| |
| * [[Pallor]]
| |
| * [[Thrombosis]]
| |
| |
| |
| * [[All-trans retinoic acid|All-''trans'' retinoic acid]] (ATRA)
| |
| * Arsenic trioxide
| |
| * [[Cytarabine]]
| |
| * [[Anthracycline]]
| |
| |
| |
| * Presence of [[Auer rods]] in promyelocytes
| |
| * High risk for early death from [[hemorrhagic]] complications<ref name="pmid21993679">{{cite journal| author=McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA et al.| title=Treatment advances have not improved the early death rate in acute promyelocytic leukemia. | journal=Haematologica | year= 2012 | volume= 97 | issue= 1 | pages= 133-6 | pmid=21993679 | doi=10.3324/haematol.2011.046490 | pmc=3248942 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21993679 }} </ref>
| |
| |-
| |
| |[[Acute lymphoblastic leukemia|'''Acute lymphoblastic leukemia''']]
| |
| |
| |
| * [[Chromosomal]] instability
| |
| * Sporadic [[mutations]]
| |
| |
| |
| * [[Anemia]]
| |
| * [[Thrombocytopenia]]
| |
| * [[Neutropenia]]
| |
| * Elevated [[LDH]]
| |
| * Elevated [[uric acid]]
| |
| * Elevated [[phosphorus]]
| |
| * Elevated [[potassium]]
| |
| * Low [[calcium]]
| |
| * Greater than 20% [[lymphoblasts]] on [[bone marrow]] aspirate
| |
| |
| |
| * [[Neurological|Neurologic]] deficits
| |
| * [[Pallor]]
| |
| * [[Lymphadenopathy]]
| |
| |
| |
| * HyperCVAD ([[cyclophosphamide]], [[vincristine]], [[doxorubicin]], [[dexamethasone]])<ref name="pmid28665419">{{cite journal| author=Terwilliger T, Abdul-Hay M| title=Acute lymphoblastic leukemia: a comprehensive review and 2017 update. | journal=Blood Cancer J | year= 2017 | volume= 7 | issue= 6 | pages= e577 | pmid=28665419 | doi=10.1038/bcj.2017.53 | pmc=5520400 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28665419 }} </ref>
| |
| * R-HyperCVAD (inclusion of [[rituximab]])
| |
| * Peg-asparaginase
| |
| * [[Intrathecal]] [[methotrexate]]
| |
| * [[Intrathecal]] [[cytarabine]]
| |
| * [[Blinatumomab]] (bispecific [[T cell]] engager)
| |
| * [[Inotuzumab ozogamicin|Inotuzumab]] ozogamycin (anti-CD22 antibody)
| |
| * [[Tisagenlecleucel]] (chimeric antigen receptor T (CAR-T) cell therapy)
| |
| * [[Stem cell transplant]]
| |
| |
| |
| * Sanctuary sites include the [[central nervous system]] ([[CNS]]) and [[testes]]<ref name="pmid23523389">{{cite journal| author=Inaba H, Greaves M, Mullighan CG| title=Acute lymphoblastic leukaemia. | journal=Lancet | year= 2013 | volume= 381 | issue= 9881 | pages= 1943-55 | pmid=23523389 | doi=10.1016/S0140-6736(12)62187-4 | pmc=3816716 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23523389 }} </ref>
| |
| |-
| |
| |[[Chronic myelogenous leukemia|'''Chronic myeloid leukemia''']]
| |
| |
| |
| * [[Translocation]] between [[Chromosome 9 (human)|chromosomes 9]] and [[Chromosome 22|22]]
| |
| * Creation of [[Bcr-abl|BCR-Abl]] [[gene]] product
| |
| |
| |
| * Elevated [[white blood cell]] count
| |
| * Presence of [[white blood cell]] precursors at various stages of maturation
| |
| * Presence of excess metamyelocytes, [[basophils]], [[eosinophils]], and [[band cells]]
| |
| |
| |
| * [[Splenomegaly]]
| |
| * [[Abdominal tenderness]]
| |
| * [[Pallor]]
| |
| * Evidence of [[infection]]
| |
| |
| |
| * [[Imatinib]]
| |
| * [[Nilotinib]]
| |
| * [[Dasatinib]]
| |
| * [[Bosutinib]]
| |
| * [[Ponatinib]]
| |
| * [[Omacetaxine]]<ref name="pmid24516334">{{cite journal| author=Chen Y, Li S| title=Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia. | journal=Onco Targets Ther | year= 2014 | volume= 7 | issue= | pages= 177-86 | pmid=24516334 | doi=10.2147/OTT.S41786 | pmc=3916637 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24516334 }} </ref>
| |
| |
| |
| * High response rate to [[tyrosine kinase inhibitors]]
| |
| * Risk for development of T315I [[kinase]] domain [[mutation]]
| |
| * Typically does not require [[stem cell transplant]]
| |
| * Three phases include chronic, accelerated, and blast phase
| |
| |-
| |
| |-
| |
| |[[Chronic lymphocytic leukemia|'''Chronic lymphocytic leukemia''']]<ref name="pmid28102226">{{cite journal| author=Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG et al.| title=Chronic lymphocytic leukaemia. | journal=Nat Rev Dis Primers | year= 2017 | volume= 3 | issue= | pages= 16096 | pmid=28102226 | doi=10.1038/nrdp.2016.96 | pmc=5336551 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28102226 }} </ref>
| |
| |
| |
| * Chromosomal instability
| |
| * Sporadic [[mutations]]
| |
| * [[Infections]]
| |
| |
| |
| * Elevated absolute [[lymphocyte]] count (in all stages)
| |
| * Presence of >5000 clonal [[B cells]] per microliter in peripheral blood
| |
| * Anemia (in Rai stage III)
| |
| * [[Thrombocytopenia]] (in Rai stage IV)
| |
| |
| |
| * [[Lymph node enlargement]] in Rai stage I
| |
| * [[Splenomegaly]] in Rai stage II
| |
| * [[Hepatomegaly]] in Rai stage II
| |
| * [[Pallor]]
| |
| * [[Bleeding]]
| |
| |
| |
| * Fludarabine
| |
| * Cyclophosphamide
| |
| * Rituximab
| |
| * Obinutuzumab<ref name="pmid28182141">{{cite journal| author=Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V| title=Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. | journal=Drug Des Devel Ther | year= 2017 | volume= 11 | issue= | pages= 295-304 | pmid=28182141 | doi=10.2147/DDDT.S104869 | pmc=5279834 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28182141 }} </ref>
| |
| * Ofatumumab
| |
| * Ibrutinib
| |
| * Venetoclax
| |
| |
| |
| * Associated with [[autoimmune hemolytic anemia]], which occurs in 10-25% of patients with CLL
| |
| * Associated with [[immune thrombocytopenia purpura]]
| |
| * Associated with [[pure red cell aplasia]]
| |
| * Treatment with corticosteroids or anti-leukemic therapy will correct the autoimmune complications of CLL
| |
| |}
| |
|
| |
|
| ==References== | | ==References== |
| {{reflist|2}} | | {{reflist|2}} |
|
| |
| [[Category:Disease]]
| |
| [[Category:Hematology]]
| |
| [[Category:Mature chapter]]
| |
|
| |
|
| |
| {{Hematology}}
| |
| {{Hematological malignancy histology}}
| |
|
| |
|
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |
| [[Category:Up-To-Date]]
| |
| [[Category:Oncology]]
| |
| [[Category:Medicine]]
| |
| [[Category:Hematology]]
| |
| [[Category:Immunology]]
| |
